Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
study id #: NCT04907162
condition: Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3, Inclusion Body Myositis, Sporadic, Facioscapulohumeral Muscular Dystrophy 1, Healthy
status: Recruiting
purpose:The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD). The secondary objectives are to evaluate whether severity and distribution of muscle pain is associated with muscle function, and to assess whether muscle pain is associated with alterations of muscle elasticity and muscle stiffness. Results of patients with neuromuscular disorders will be compared to age- and gender-matched healthy volunteers. Approx. 70 patients with neuromuscular disorders and 20 healthy volunteers will be enrolled, including patients with the following neuromuscular disorders: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD), genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). The duration of patient recruitment will be around 12 months.
intervention: Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory, Fatigue Severity and Disability Scale (FSS), Quick Motor Function Test, Handheld Dynamometry (HHD), Six-minute walk test (6MWT), Pressure pain threshold, Myotonometer Assessment, Vital signs, Borg Scale
results: https://clinicaltrials.gov/ct2/show/results/NCT04907162
last updated: February 04, 2022
-
Alex Fay, PhDDr. Alex Fay is a pediatric neurologist ...
-
Spinal Muscular Atrophy With Predominant Lower Extremity (SMA-LED) With no Signs Other Than Pure Motor Symptoms at t...Background: Mutations in the cytoplasmic...
-
Artist With SMA Pens Song ‘SPACES’ About Looking Beyond DisabilityA song written and performed by an artis...
-
STR1VE-EU Trial Shows Efficacy of Onasemnogene Abeparvovec in Spinal Muscular AtrophyOnasemnogene abeparvovec gene replacemen...
-
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
-
The Pediatric SMA Clinic – Columbia UniversityThe Pediatric SMA Clinic is committed to...
-
Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian PerspectiveSpinal muscular atrophy (SMA) is the sec...